Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT03727399
Other study ID # 2018-01110
Secondary ID
Status Enrolling by invitation
Phase
First received
Last updated
Start date October 1, 2018
Est. completion date December 31, 2025

Study information

Verified date March 2024
Source Mabylon AG
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The project examines the hypothesis that monoclonal allergen-neutralizing antibodies can be recombinantly produced from B lymphocytes isolated from pollen allergic patients. Patient samples suitable for antibody cloning are selected based on seroprofiling for the respective allergens. The study aims at isolating lymphocytes from patients with potential allergen-neutralizing IgG in serum and to clone antibodies from antibody gene sequences obtained from B cells of those patients.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 300
Est. completion date December 31, 2025
Est. primary completion date December 31, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - History of allergic rhinitis, conjunctivitis or asthma due to sensitization to grass- or birch Allergens - Male or female patients older than 18 years - Written informed consent for providing blood and also to allow experimental manipulation Exclusion Criteria: - Age < 18 years - Any corticosteroids within the last three days - Oral corticosteroid therapy within the last ten days - Parenteral depot corticosteroids within the last three months

Study Design


Related Conditions & MeSH terms


Intervention

Other:
blood withdrawal
Blood withdrawal

Locations

Country Name City State
Switzerland Immunologie Zentrum Zürich Zürich

Sponsors (1)

Lead Sponsor Collaborator
Mabylon AG

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Antibody profiling Analysis and IgG profiling of specific antibodies binding major grass- and tree-pollen allergens in allergic patients. October 2018 - September 2021
See also
  Status Clinical Trial Phase
Completed NCT01500642 - Comparison of the Efficacy and the Safety of Different Schedules of Administration of Sub-lingual Immunotherapy Phase 3
Completed NCT00263627 - Safety and Efficacy of Specific Immunotherapy With an Aluminium Hydroxide-adsorbed Allergoid Preparation of Birch Pollen Allergens Phase 3
Terminated NCT04874714 - Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis Phase 3
Completed NCT04622917 - Methylprednisolone Injections Treating Birch Pollen Induced Allergic Rhinitis. Phase 4